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Utility of new classification based on clinical and
lesional factors after self-expandable nitinol
stenting in the superficial femoral artery
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Atsushi Tosaka, MD,a Hiroyoshi Yokoi, MD,e andMasakiyo Nobuyoshi, MD,a Kitakyushu, Amagasaki,
Yokohama, and Sendai, Japan
Background: The aim of this study was to investigate the predictive value of clinical classification schemes that assess
primary patency after self-expandable nitinol stent in the superficial femoral artery (SFA).
Methods: This study was a multicenter retrospective study of prospective databases. From April 2004 to December 2009,
1001 limbs (807 patients) that underwent successful nitinol stent implantation for de novo SFA lesions were identified
and analyzed. Primary patency was defined as treated vessel without restenosis (defined as >2.4 of peak systolic velocity
ratio by duplex) and repeat revascularization. Six items were included in the classification: female, diabetes, dialysis,
critical limb ischemia (CLI), lesion length > 150 mm, and poor runoff; the FeDCLIP score. A lesion length >150 mm
was scored as 2 points. The others were assigned 1 point each. The scores of 0 to 2, 3 to 4, and >5 points were classified
as low-, moderate-, and high-risk patients, respectively. Outcome measures were primary and secondary patency and
all-cause mortality up to 6 years in each risk group.
Results: The mean follow-up interval was 26.8  14.6 months. Primary patencies were 85.7%, 77.3%, and 74.2% in the
low-risk group; 71.5%, 54.7%, and 51.9% in the moderate-risk group; and 53.0%, 24.3%, and 20.8% in the high-risk
group at 1, 3, and 5 years, respectively. The secondary patencies were 94.6%, 92.3%, and 90.8% in the low-risk group;
89.5%, 83.1%, and 83.1% in the moderate-risk group; and 82.7%, 73.1%, and 73.1% in the high-risk group at 1, 3, and
5 years, respectively. There were significant differences in primary and secondary patency among the three risk groups
(P < .0001 and P < .0001, respectively). Overall survival rates were 96.8%, 89.5%, and 81.8% in the low-risk group;
91.5%, 74.4%, and 68.7% in the moderate-risk group; and 78.2%, 63.2%, and 48.7% in the high-risk group at 1, 3, and
5 years, respectively. There were also significant differences in mortality (P < .0001).
Conclusions: New classification schemes based on FeDCLIP score were useful for risk stratification in vessel patency and
mortality after self-expandable nitinol stenting for SFA disease. ( J Vasc Surg 2011;54:1058-66.)
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tIn endovascular therapy (EVT) for the superficial
femoral artery (SFA), use of the self-expandable nitinol
stent for primary stenting of long lesions has produced
favorable results, compared with balloon angioplasty.1-4
In addition, stent placement is acceptable as a bailout for
suboptimal results after balloon angioplasty, such as
flow-limiting dissection and acute recoil. However, a
decrease in patency in the chronic phase accompanied by
restenosis is still a major limitation of EVT, even with use
of a self-expandable nitinol stent.5 In the TransAtlantic
InterSociety Consensus (TASC) II classification,6 pa-
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1058ients are placed in classes A to D based on lesion
ackground, although with consideration of patency in
he chronic phase. However, the outcome after revascu-
arization depends not only on lesion background, but
lso on clinical factors such as diabetes, renal failure, and
ritical limb ischemia.6 Thus, a complete classification of
linical outcome may require inclusion of these factors
nd patency after placement of a self-expandable nitinol
tent. In this study, we examined the clinical outcome of
atients treated with a self-expandable nitinol stent in
he SFA field based on quantification of risk factors
elected from historical data.
ETHODS
tudy population
The study was performed as a multicenter, prospec-
ive maintained database, retrospective analysis. Between
anuary 2004 and December 2009, 2787 consecutive
atients underwent EVT for SFA disease at each hospital
nvolved in the study. Of these cases, 1980 patients were
xcluded because of asymptomatic or unknown symp-
oms before EVT (five patients), age 40 years (four
atients), a follow-up interval6 months (106 patients),
reatment with angioplasty alone (918 patients), rest-
notic lesions (425 patients), use of a balloon- or self-
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Volume 54, Number 4 Soga et al 1059expandable metallic stent (117 patients), technical failure
(106 patients), history of lower extremity bypass surgery or
EVT (235 patients), or acute-onset limb ischemia (64
patients). Therefore, 807 patients (1001 limbs) who un-
derwent successful EVT with a nitinol stent for de novo
lesions were identified retrospectively and included in the
analysis.
This study population included the 511 patients
whose midterm result was reported previously.7 Baseline
clinical characteristics and procedural data were collected
from each hospital database. Clinical evaluation was per-
formed at baseline and every 6 months thereafter. The
Table I. Patient characteristics
Total
n  807 n
Age (years) 72.3  7.2 72.
75 years (%) 365 (45) 170
Male gender (%) 556 (68.9) 328
Body mass index 22.4  2.4 22.
25 (%) 68 (18.4) 39
Hypertension (%) 691 (85.6) 330
Hyperlipidemia (%) 313 (38.8) 147
Diabetes (%) 494 (61.2) 190
Current smoker (%) 261 (32.3) 154
Previous smoker 228 (28.3) 62
Never smoked 318 (39.4) 179
Hemodialysis (%) 160 (19.8) 37
Cerebrovascular disease (%) 212 (26.3) 77
Coronary artery disease (%) 432 (53.5) 202
Critical limb ischemia (%) 208 (25.8) 29
Medications
Aspirin (%) 747 (92.6) 368
Thienopyridines (%) 405 (50.4) 220
Other antiplatelet drug (%) 495 (61.5) 257
Cilostazol (%) 476 (59.0) 225
Warfarin (%) 87 (10.8) 42
Statins (%) 279 (34.8) 140
Table II. Lesion characteristics
Lesion characteristics
Total
n  1001
L
n 
Lesion length (mm) 145.3  70.3 93.7
150 mm 454 (45.4) 70
RVD (mm) 5.2  0.7 5.3
Total stent length (mm) 155.8  81.8 104.4
No. of stents implanted 1.8  0.8 1.4
Chronic total occlusion (%) 545 (54.4) 204
Calcified lesiona (%) 416 (41.6) 189
Preprocedure ABI 0.59  0.15 0.63
Postprocedure ABI 0.85  0.14 0.91
Poor runoffb (%) 352 (35.2) 71
Type of nitinol stent
Luminexx (%) 253 (25.4) 127
SMART (%) 747 (74.6) 354
Stent fracture (%) 101 (10.1) 30
TASC II C/D 501 (50.1) 102
ABI, Ankle-brachial index; TASC, TransAtlantic InterSociety Consensus.
aCalcified lesion defined as obvious densities noted within the apparent vasc
bPoor runoff was defined as one vessel or none of below-the-knee runoff.mean follow-up interval of the 697 survivors was 26.8  (4.6 months. The study protocol was approved by the
ospital ethics committees, and the study was performed in
ccordance with the Declaration of Helsinki. Written in-
ormed consent was obtained from every patient.
This study (FeDCLIP Registry) is registered with the
niversity HospitalMedical InformationNetwork-Clinical
rials Registry (UMIN-CTR), as accepted by the Interna-
ional Committee of Medical Journal Editors (No.
MIN000004793).
rocedures and follow-up
All patients were medicated with dual antiplatelet therapy
Moderate
n  310
High
n  102 P value
.6 72.6  9.1 73.0  10.2 .46
0) 143 (46.1) 52 (51.0) .33
0) 193 (62.3) 35 (34.3) .0001
.0 22.1  3.2 21.7  2.8 .009
2) 25 (16.1) 4 (8.5) .045
5) 272 (87.7) 89 (87.3) .25
2) 134 (43.2) 32 (31.4) .069
1) 220 (71.0) 84 (82.4) .0001
0) 89 (28.7) 18 (6.9) .0001
7) 100 (32.3) 66 (64.7) .0001
3) 121 (39.0) 18 (17.6) .0001
) 74 (23.9) 49 (48.0) .0001
5) 93 (30.0) 42 (41.2) .0001
1) 168 (54.2) 62 (60.8) .21
) 95 (30.6) 84 (82.4) .0001
2) 287 (92.6) 92 (9/.2) .60
7) 139 (45.1) 46 (46.0) .013
1) 184 (59.5) 54 (53.5) .068
0) 196 (41.2) 55 (53.9) .13
7) 36 (11.7) 9 (9.0) .75
7) 114 (37.0) 25 (24.8) .071
Moderate
n  388
High
n  132 P value
.2 147.4  51.4 178.0  30.9 .0001
) 257 (66.2) 127 (96.2) .0001
5.2  0.8 5.3  0.9 .91
.9 189.6  89.5 244.1  67.5 .0001
2.1  0.9 2.5  0.7 .0001
) 254 (65.5) 87 (65.9) .0001
) 169 (43.6) 58 (43.9) .37
1 0.57  0.22 0.46  0.26 .0001
6 0.86  0.20 0.83  0.22 .007
) 170 (43.8) 111 (84.1) .0001
) 86 (22.2) 41 (31.1) .20
) 302 (77.8) 91 (68.9)
55 (14.2) 16 (12.1) .0004
) 277 (71.4) 122 (92.4) .0001
all in the angiogram.Low
 395
0  8
(43.
(83.
9  3
(23.
(83.
(37.
(48.
(39.
(15.
(45.
(9.4
(19.
(51.
(7.3
(93.
(55.
(65.
(57.
(10.ow
481
 53
(14.6
 0.8
 67
 0.7
(42.4
(39.3
 0.2
 0.1
(14.8
(26.4
(73.6
(6.2)
(21.2aspirin 100mg/day clopidogrel 75mg/day or ticlopidine
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October 20111060 Soga et al200 mg/day) before the procedure. After insertion of a 6- or
7-Fr sheath, an intra-arterial bolus of 5000 IU of heparin was
injected and supplemented as required to maintain an active
clotting time of 200 seconds. A 0.035-, 0.018-, or 0.014-
inch guidewire was used to cross the lesion. After passing the
wire, balloon angioplasty was performed. All lesions were
dilated with an optimally-sized balloon. If a suboptimal result
was found after dilatation, a stentwas implanted. Two types of
nitinol stents were used: Luminexx (Bard, Murray Hill, NJ)
and SMART (Cordis Johnson & Johnson, Bridgewater, NJ).
The stent type was determined by the operators and the stent
size was chosen to be 1 to 2 mm larger than the reference
vessel diameter. After the procedure, all patients were pre-
scribed lifelong aspirin (100mg/day) and prolonged (at least
1 month) clopidogrel 75 mg/day or ticlopidine 200mg/day
was recommended. The presence of stent fracture and duplex
ultrasound of the stented vessel were monitored every 6
Fig 1. Overall primary and secondary patency in 1001
in superficial femoral artery.months. ltudy outcome measures
The primary outcome measure was primary patency
fter treatment, and the secondary outcome measures were
econdary patency and overall survival.
efinitions
FeDCLIP score. The outcome of endovascular treat-
ent depends on clinical and anatomical factors. According
o TASC II,6 diabetes, renal failure (dialysis), and critical
imb ischemia (CLI) are the common clinical factors that
ffect the patency rate. The key anatomical factors are the
everity of the lesion in the outflow artery (poor runoff) and
he length of the stenosis or occlusion. Female gender is
lso an important factor.8-10 However, the TASC II classi-
cation is based only on anatomical factors, and this is a
imitation in evaluation of patency. Therefore, we estab-
after stent placement with self-expandable nitinol stentlimbsished a new classification based on historical data as mark-
r
e
t
i
v
r
fi
U
g
c
m
m
d
m
t
w-, m
JOURNAL OF VASCULAR SURGERY
Volume 54, Number 4 Soga et al 1061ers of patency, with the goal of using simple items for this
purpose. Six items are included in the classification: female,
diabetes, dialysis, CLI, lesion length 150 mm, and poor
runoff: the FeDCLIP score. Based on the similar restenosis
rates of stent implantation in the SFA for a lesion 130
mm,1,2,11 and taking into account that lesions in TASC II
classes B and C have differences in patency,7,12 a score of 2
points was assigned to a lesion 150 mm. Since lesion
length is a major factor in restenosis, a lesion length 150
mm was scored as 2 points, while female, diabetes, dialysis,
CLI, and poor runoff were each scored as 1 point. Thus, the
total score ranged from 0 to 7 points, and scores of 0 to 2,
3 to 4, and 5 points were used to indicate low-risk,
moderate-risk, and high-risk patients, respectively. For ex-
ample, a female (1) patient with diabetes (1), CLI (1), and
a SFA lesion of 160 mm (2) would be classified as high risk
Fig 2. Primary patency among lobased on a FeDCLIP score of 5 points. pPrimary patency was defined as treated vessel without
estenosis and repeat revascularization that remained pat-
nt. Assisted-primary patency was defined as a patent
reated vessel that underwent repeat revascularization to
mprove patency. Secondary patency was defined as a target
essel that subsequently become totally occluded and was
eopened by repeat revascularization. Restenosis was de-
ned as 2.4 of peak systolic velocity ratio by duplex.13
ndetectable signal in stented segments by duplex was
raded as complete occlusion. Stent fracture was defined as
lear interruption of stent struts identified by x-ray from
ore than two projections, with resulting kink or misalign-
ent along the axial length of the stent. Coronary artery
isease (CAD) was defined as stable angina with docu-
ented CAD, history of percutaneous coronary interven-
ion, history of coronary artery bypass graft surgery, or
oderate-, and high-risk patients.revious myocardial infarction. Cerebrovascular disease
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October 20111062 Soga et al(CVD) was defined as a hospital or neurologist report with
the diagnosis of transient ischemic attack or ischemic
stroke. Below-the-knee (BTK) runoff was assessed by an-
giography before or after procedure. Poor runoff was de-
fined as one or no BTK vessel runoff.
Statistical analysis
Continuous variables were expressed as mean  SD.
Differences among treatment groups were evaluated by
analysis of variance for continuous variables and by the 2
or Fisher exact test for categorical variables. Survival curves
were estimated by the Kaplan-Meier method and compared
with the log-rank test. A probability value of .05 was
considered statistically significant.
RESULTS
Patient and lesion characteristics. The age of the
Fig 3. Secondary patency among807 patients (1001 limbs) ranged from 40 to 94 years old 5mean, 72.3  7.2 years old). The characteristics of the
atients and lesions are shown in Tables I and II. The
ercentages of patients with intermittent claudication and
LI were 74.2% and 25.8%, respectively. Never-smoked
atients were inversely proportional to risk criteria stratifi-
ation. The mean lesion length was 145.3 70.3 mm, and
otal stent length was 155.8  81.8 mm. In the TASC II
lassification, 500 (50.0%) and 501 (50.0%) patients were
n classes A/B and C/D, respectively. Patients with poor
unoff vessel numbered 348 (34.8%).
Outcome measures. The overall primary patencies
ere 76.3%, 62.6%, and 57.6% at 1, 3, and 5 years; assisted-
rimary patencies were 84.9%, 77.6%, and 75.5% at 1, 3,
nd 5 years; and the secondary patencies were 91.3%,
6.9%, and 86.1% at 1, 3, and 5 years (Fig 1). There is no
ignificant difference of primary patency between the two
ypes of implanted stent at 5 years (Luminexx vs SMART;
moderate-, and high-risk patients.8.7% vs 58.3%; P  .30; log rank test).
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shown in Fig 2. The primary patencies were 85.7%,
77.3%, and 74.2% at 1, 3, and 5 years in the low-risk
group; 71.5%, 54.7%, and 51.9% at 1, 3, and 5 years in
the moderate-risk group; and 53.0%, 24.3%, and 20.8%
at 1, 3, and 5 years in the high-risk group. The primary
patency was favorable in the low-risk group, and poorer
patencies were found in patients with more risk factors.
There were significant differences in primary patencies
between each pair of risk groups (low vs moderate, P 
.0001; moderate vs high, P  .0001; low vs high, P 
.0001; log rank test).
Similar results were obtained for secondary patency
(Fig 3). The secondary patencies were 94.6%, 92.3%, and
90.8% at 1, 3, and 5 years in the low-risk group; 89.5%,
83.1%, and 83.1% at 1, 3, and 5 years in the moderate-
Fig 4. Overall survival in low-risk group; and 82.7%, 73.1%, and 73.1% at 1, 3, and 5 rears in the high-risk group. Patients with more risk
actors had lower secondary patencies. Secondary pa-
ency in the high-risk group tended to be lower than that
n the moderate-risk group (P  .087; log rank test) and
howed significant differences between the other two
airs of groups (low vs moderate, P  .001; low vs high,
 .0001; log rank test).
Regarding mortality, the overall survival rates were
6.8%, 89.5%, and 81.8% at 1, 3, and 5 years in the
ow-risk group; 91.5%, 74.4%, and 68.7% at 1, 3, and 5
ears in the moderate-risk group; and 78.2%, 63.2%, and
8.7% at 1, 3, and 5 years in the high-risk group. Patients
ith more risk factors had higher mortalities (Fig 4).
here were significant differences in mortality between
ach pair of risk groups (low vs moderate, P  .0001;
oderate vs high, P .0004; low vs high, P .0001; log
erate-, and high-risk patients.ank test).
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In this study, risk classification (low, moderate, and
high) using scores for six items was useful for prediction of
patency and mortality. The TASC II classification for le-
sions includes four groups from A to D, but it is not
correlated with therapeutic results in the chronic phase.7,12
In this study, we also found no significant differences in
primary patency between TASC II A versus B and C versus
D categories (A vs B, P  .37; C vs D, P  .52; log rank
test), although there were significant differences between
all other pair-wise comparisons (Fig 5). In addition, some
patients with TASC II class C/D lesions showed good
outcomes, even though chronic-phase patency for these
lesions is generally considered to be poor. Examination of
risk classification based on the FeDCLIP score for primary
patency in only TASC II class C/D lesions (501 limbs)
showed that as risks increase, primary patency is signifi-
cantly reduced (low vs moderate vs high risk; 70.5% vs
Fig 5. Primary patency among TransAtlantic46.5% vs 18.5% at 5 years, P .0001; log rank test; Fig 6). shis suggests that for TASC II class C/D lesions, relatively
ood outcomes after stent treatment are likely if there are
ew risk factors other than a large lesion length. If this is not
he case, good outcomes in the chronic phase are unlikely,
nd surgery should be considered when possible. These
esults were probably due to most TASC II A/B cases
aving a stenosis with a lesion length 15 cm and most
ASC II C/D cases having an occlusion with lesion length
15 cm. Thus, a large difference in patency is likely be-
ween TASC II A/B and C/D cases, but a large difference
n patency between A and B or C and D cases is unlikely.
his is because a 5- to 10-cm difference in lesion length
ight be countered by the impact of the stent, in contrast
o balloon angioplasty.
Stratification of patient risk is extremely important in
apidly prevailing EVT.14-16 Based on the results of this
tudy, we suggested that a classification including lesion
ackground and clinical factors might be more useful for
rSociety Consensus (TASC) II classification.tratification of risks associated with patency in the chronic
p
T
p
c
p
d
E
t
a
e
d
t
C
f
i
t
t
i
JOURNAL OF VASCULAR SURGERY
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ground only. In TASC II,6 it is also suggested that lesions
in the lower extremities can be characterized by several
lesions at different levels, and thus a limit of TASC II is that
patients should be classified with a focus placed on an
individual lesion. In addition, a significant difference in
individual risks related to mortality was also found in the
classification used in this study. The Bypass versus Angio-
plasty in Severe Ischaemia of the Leg (BASIL) study17
showed that patients with severe ischemia in the lower
extremities with a durable autogenous vein and a life expec-
tancy of 2 years should receive surgical revascularization
and that those without this expectation should undergo
EVT.18 We consider that patency and life expectancy
should be taken into consideration in determining thera-
peutic policy for both CLI and peripheral artery disease
patients. Thus, evaluation of patency and life expectancy
based on the risk factors established in this study is clinically
important.
This study was performed with patients with SFA dis-
Fig 6. Primary patency in low-, moderate-, and high-r
InterSociety Consensus.ease who received EVT with a nitinol stent, and no com- tarison with surgical revascularization was performed.
hus, the results do not indicate whether EVT should be
erformed instead of surgical revascularization. A future
omparison of the results of this study with those for bypass
rocedures in the stratified risk groups is required to ad-
ress this issue. It is likely that patients with high risks in
VT will also be high-risk cases for surgical revasculariza-
ion, but this requires clarification in a further study.
The patient and lesion backgrounds can vary widely
mong facilities, depending on the particular expertise of
ach facility for treatment of diseases such as CAD or
iabetes and performance of dialysis. All four facilities in
his study were cardiovascular centers that focused on
AD. There were no significant differences among the
acilities in mortality and patency rates, but a further study
s required to determine whether similar results are ob-
ained in other specialized facilities.
This study showed that clinical risk factors are impor-
ant for vessel patency after stent treatment for SFA lesions,
n addition to the lesion background. When determining
tients with TASC II C/D lesion. TASC, TransAtlanticisk pahe treatment policy for an SFA lesion, the optimum revas-
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account both the difficulty of the lesion treatment and
other background factors. Risk classification based on the
FeDCLIP score is likely to be useful in such cases. How-
ever, the FeDCLIP score includes six outcomes selected
based on previous data on vessel patency, taking versatility
and clinical convenience into account. In addition, factors
involved with patency after EVT for SFA have been de-
scribed, and new factors are likely to be reported. Prospec-
tive and large-scale validations are needed to show the
adequacy of FeDCLIP scores for predicting outcomes.
Increased accumulation of findings will allow establishment
of an improved classification with greater clinical utility.
There are several limitations in the current study. First,
we performed a retrospective analysis, although in a large-
scale, multicenter study. Second, only two types of nitinol
stents were implanted, and further investigation of the new
generation of nitinol stents is needed. Third, we prepared a
classification method based on scoring of six items, includ-
ing clinical and anatomical factors to evaluate patency and
mortality. We selected these items for their simplicity and
availability in clinical reports. However, there is no general
consensus on the importance of each item, and accumula-
tion of more data is required to examine this issue. Finally,
the subjects of this study were Japanese, and their physical
constitution and muscle strength may differ from those of
Western patients. Thus, a further study is required to
examine whether similar results are obtained in other races.
CONCLUSION
Despite these limitations, the results in this study
suggest that the new classification scheme based on the
FeDCLIP score, which takes into account clinical factors as
well as lesion severity, was useful for risk stratification for
vessel patency and mortality after self-expandable nitinol
stenting for SFA disease.
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